The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

Completed

Conditions studied: Aging

In brief

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Key facts

Study ID

NCT06550271

Run by

AgelessRx

People needed

67

Starts

2023-04-25

Expected to finish

2023-12-15

Last updated by the study team

2024-08-13

Who can join

Age: 40 and older, up to 120. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Receive AgelessRx's standard Rapamycin treatment protocol
• Opted to complete at least 1 blood draw at their local Quest Lab

You may not qualify if…

• Not approved for current AgelessRx standard Rapamycin treatment
• History of uncontrolled disease
• Unable to complete at least 1 blood draw at their local Quest Lab

Where it is running

• AgelessRx — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.